- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).
They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.
In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.
According to our latest study, the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market size was valued at USD 4822.1 million in 2022 and is forecast to a readjusted size of USD 8545.3 million by 2029 with a CAGR of 8.5% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor key players include AstraZeneca, Tesaro, Merck & Co, etc. Global top three manufacturers hold a share about 90%.
North America is the largest market, with a share about 70%, followed by Europe and Emerging Country, both have a share about 25 percent.
In terms of product, Lynparza is the largest segment, with a share over 65%. And in terms of application, the largest application is Ovarian Cancer, followed by Breast Cancer.
This report is a detailed and comprehensive analysis for global PARP (Poly ADP-Ribose Polymerase) Inhibitor market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for PARP (Poly ADP-Ribose Polymerase) Inhibitor
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AstraZeneca, Tesaro, Merck & Co, Clovis Oncology and Pfizer, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
PARP (Poly ADP-Ribose Polymerase) Inhibitor market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Lynparza
Zejula
Rubraca
Talzenna
Other
Market segment by Application
Ovarian Cancer
Breast Cancer
Other
Major players covered
AstraZeneca
Tesaro
Merck & Co
Clovis Oncology
Pfizer
GSK
Zai Lab
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe PARP (Poly ADP-Ribose Polymerase) Inhibitor product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, with price, sales, revenue and global market share of PARP (Poly ADP-Ribose Polymerase) Inhibitor from 2018 to 2023.
Chapter 3, the PARP (Poly ADP-Ribose Polymerase) Inhibitor competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the PARP (Poly ADP-Ribose Polymerase) Inhibitor breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and PARP (Poly ADP-Ribose Polymerase) Inhibitor market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of PARP (Poly ADP-Ribose Polymerase) Inhibitor.
Chapter 14 and 15, to describe PARP (Poly ADP-Ribose Polymerase) Inhibitor sales channel, distributors, customers, research findings and conclusion.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of PARP (Poly ADP-Ribose Polymerase) Inhibitor
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Lynparza
1.3.3 Zejula
1.3.4 Rubraca
1.3.5 Talzenna
1.3.6 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Ovarian Cancer
1.4.3 Breast Cancer
1.4.4 Other
1.5 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size & Forecast
1.5.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value (2018 & 2022 & 2029)
1.5.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity (2018-2029)
1.5.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price (2018-2029)
2 Manufacturers Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
2.1.4 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 AstraZeneca Recent Developments/Updates
2.2 Tesaro
2.2.1 Tesaro Details
2.2.2 Tesaro Major Business
2.2.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
2.2.4 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Tesaro Recent Developments/Updates
2.3 Merck & Co
2.3.1 Merck & Co Details
2.3.2 Merck & Co Major Business
2.3.3 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
2.3.4 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Merck & Co Recent Developments/Updates
2.4 Clovis Oncology
2.4.1 Clovis Oncology Details
2.4.2 Clovis Oncology Major Business
2.4.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
2.4.4 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Clovis Oncology Recent Developments/Updates
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
2.5.4 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Pfizer Recent Developments/Updates
2.6 GSK
2.6.1 GSK Details
2.6.2 GSK Major Business
2.6.3 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
2.6.4 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 GSK Recent Developments/Updates
2.7 Zai Lab
2.7.1 Zai Lab Details
2.7.2 Zai Lab Major Business
2.7.3 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
2.7.4 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Zai Lab Recent Developments/Updates
3 Competitive Environment: PARP (Poly ADP-Ribose Polymerase) Inhibitor by Manufacturer
3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Manufacturer (2018-2023)
3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturer (2018-2023)
3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of PARP (Poly ADP-Ribose Polymerase) Inhibitor by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturer Market Share in 2022
3.4.2 Top 6 PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturer Market Share in 2022
3.5 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Overall Company Footprint Analysis
3.5.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Region Footprint
3.5.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Company Product Type Footprint
3.5.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Region
4.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Region (2018-2029)
4.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Region (2018-2029)
4.1.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Region (2018-2029)
4.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value (2018-2029)
4.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value (2018-2029)
4.4 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value (2018-2029)
4.5 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value (2018-2029)
4.6 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2018-2029)
5.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Type (2018-2029)
5.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2018-2029)
6.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Application (2018-2029)
6.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Application (2018-2029)
7 North America
7.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2018-2029)
7.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2018-2029)
7.3 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country
7.3.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Country (2018-2029)
7.3.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2018-2029)
8.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2018-2029)
8.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country
8.3.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Country (2018-2029)
8.3.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Region
9.3.1 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2018-2029)
10.2 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2018-2029)
10.3 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country
10.3.1 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Country (2018-2029)
10.3.2 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country
11.3.1 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Drivers
12.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Restraints
12.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of PARP (Poly ADP-Ribose Polymerase) Inhibitor and Key Manufacturers
13.2 Manufacturing Costs Percentage of PARP (Poly ADP-Ribose Polymerase) Inhibitor
13.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Process
13.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Typical Distributors
14.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
List of Tables
Table 1. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 4. AstraZeneca Major Business
Table 5. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
Table 6. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. AstraZeneca Recent Developments/Updates
Table 8. Tesaro Basic Information, Manufacturing Base and Competitors
Table 9. Tesaro Major Business
Table 10. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
Table 11. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Tesaro Recent Developments/Updates
Table 13. Merck & Co Basic Information, Manufacturing Base and Competitors
Table 14. Merck & Co Major Business
Table 15. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
Table 16. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Merck & Co Recent Developments/Updates
Table 18. Clovis Oncology Basic Information, Manufacturing Base and Competitors
Table 19. Clovis Oncology Major Business
Table 20. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
Table 21. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Clovis Oncology Recent Developments/Updates
Table 23. Pfizer Basic Information, Manufacturing Base and Competitors
Table 24. Pfizer Major Business
Table 25. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
Table 26. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Pfizer Recent Developments/Updates
Table 28. GSK Basic Information, Manufacturing Base and Competitors
Table 29. GSK Major Business
Table 30. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
Table 31. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. GSK Recent Developments/Updates
Table 33. Zai Lab Basic Information, Manufacturing Base and Competitors
Table 34. Zai Lab Major Business
Table 35. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
Table 36. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Zai Lab Recent Developments/Updates
Table 38. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 39. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturer (2018-2023) & (USD Million)
Table 40. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Manufacturer (2018-2023) & (USD/Unit)
Table 41. Market Position of Manufacturers in PARP (Poly ADP-Ribose Polymerase) Inhibitor, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 42. Head Office and PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Site of Key Manufacturer
Table 43. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Company Product Type Footprint
Table 44. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Company Product Application Footprint
Table 45. PARP (Poly ADP-Ribose Polymerase) Inhibitor New Market Entrants and Barriers to Market Entry
Table 46. PARP (Poly ADP-Ribose Polymerase) Inhibitor Mergers, Acquisition, Agreements, and Collaborations
Table 47. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Region (2018-2023) & (K Units)
Table 48. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Region (2024-2029) & (K Units)
Table 49. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Region (2018-2023) & (USD Million)
Table 50. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Region (2024-2029) & (USD Million)
Table 51. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Region (2018-2023) & (USD/Unit)
Table 52. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Region (2024-2029) & (USD/Unit)
Table 53. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2018-2023) & (K Units)
Table 54. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2024-2029) & (K Units)
Table 55. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Type (2018-2023) & (USD Million)
Table 56. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Type (2024-2029) & (USD Million)
Table 57. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Type (2018-2023) & (USD/Unit)
Table 58. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Type (2024-2029) & (USD/Unit)
Table 59. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2018-2023) & (K Units)
Table 60. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2024-2029) & (K Units)
Table 61. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Application (2018-2023) & (USD Million)
Table 62. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Application (2024-2029) & (USD Million)
Table 63. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Application (2018-2023) & (USD/Unit)
Table 64. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Application (2024-2029) & (USD/Unit)
Table 65. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2018-2023) & (K Units)
Table 66. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2024-2029) & (K Units)
Table 67. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2018-2023) & (K Units)
Table 68. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2024-2029) & (K Units)
Table 69. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Country (2018-2023) & (K Units)
Table 70. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Country (2024-2029) & (K Units)
Table 71. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Country (2018-2023) & (USD Million)
Table 72. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Country (2024-2029) & (USD Million)
Table 73. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2018-2023) & (K Units)
Table 74. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2024-2029) & (K Units)
Table 75. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2018-2023) & (K Units)
Table 76. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2024-2029) & (K Units)
Table 77. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Country (2018-2023) & (K Units)
Table 78. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Country (2024-2029) & (K Units)
Table 79. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Country (2018-2023) & (USD Million)
Table 80. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Country (2024-2029) & (USD Million)
Table 81. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2018-2023) & (K Units)
Table 82. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2024-2029) & (K Units)
Table 83. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2018-2023) & (K Units)
Table 84. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2024-2029) & (K Units)
Table 85. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Region (2018-2023) & (K Units)
Table 86. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Region (2024-2029) & (K Units)
Table 87. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Region (2018-2023) & (USD Million)
Table 88. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Region (2024-2029) & (USD Million)
Table 89. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2018-2023) & (K Units)
Table 90. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2024-2029) & (K Units)
Table 91. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2018-2023) & (K Units)
Table 92. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2024-2029) & (K Units)
Table 93. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Country (2018-2023) & (K Units)
Table 94. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Country (2024-2029) & (K Units)
Table 95. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Country (2018-2023) & (USD Million)
Table 96. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Country (2024-2029) & (USD Million)
Table 97. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2018-2023) & (K Units)
Table 98. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2024-2029) & (K Units)
Table 99. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2018-2023) & (K Units)
Table 100. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2024-2029) & (K Units)
Table 101. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Region (2018-2023) & (K Units)
Table 102. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Region (2024-2029) & (K Units)
Table 103. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Region (2018-2023) & (USD Million)
Table 104. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Region (2024-2029) & (USD Million)
Table 105. PARP (Poly ADP-Ribose Polymerase) Inhibitor Raw Material
Table 106. Key Manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor Raw Materials
Table 107. PARP (Poly ADP-Ribose Polymerase) Inhibitor Typical Distributors
Table 108. PARP (Poly ADP-Ribose Polymerase) Inhibitor Typical Customers
List of Figures
Figure 1. PARP (Poly ADP-Ribose Polymerase) Inhibitor Picture
Figure 2. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value Market Share by Type in 2022
Figure 4. Lynparza Examples
Figure 5. Zejula Examples
Figure 6. Rubraca Examples
Figure 7. Talzenna Examples
Figure 8. Other Examples
Figure 9. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 10. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value Market Share by Application in 2022
Figure 11. Ovarian Cancer Examples
Figure 12. Breast Cancer Examples
Figure 13. Other Examples
Figure 14. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 15. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 16. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity (2018-2029) & (K Units)
Figure 17. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price (2018-2029) & (USD/Unit)
Figure 18. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity Market Share by Manufacturer in 2022
Figure 19. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value Market Share by Manufacturer in 2022
Figure 20. Producer Shipments of PARP (Poly ADP-Ribose Polymerase) Inhibitor by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 21. Top 3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturer (Consumption Value) Market Share in 2022
Figure 22. Top 6 PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturer (Consumption Value) Market Share in 2022
Figure 23. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity Market Share by Region (2018-2029)
Figure 24. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value Market Share by Region (2018-2029)
Figure 25. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value (2018-2029) & (USD Million)
Figure 26. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value (2018-2029) & (USD Million)
Figure 27. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value (2018-2029) & (USD Million)
Figure 28. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value (2018-2029) & (USD Million)
Figure 29. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value (2018-2029) & (USD Million)
Figure 30. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity Market Share by Type (2018-2029)
Figure 31. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value Market Share by Type (2018-2029)
Figure 32. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Type (2018-2029) & (USD/Unit)
Figure 33. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity Market Share by Application (2018-2029)
Figure 34. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value Market Share by Application (2018-2029)
Figure 35. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Application (2018-2029) & (USD/Unit)
Figure 36. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity Market Share by Type (2018-2029)
Figure 37. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity Market Share by Application (2018-2029)
Figure 38. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity Market Share by Country (2018-2029)
Figure 39. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value Market Share by Country (2018-2029)
Figure 40. United States PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 43. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity Market Share by Type (2018-2029)
Figure 44. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity Market Share by Application (2018-2029)
Figure 45. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity Market Share by Country (2018-2029)
Figure 46. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value Market Share by Country (2018-2029)
Figure 47. Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. France PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. United Kingdom PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 52. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity Market Share by Type (2018-2029)
Figure 53. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity Market Share by Application (2018-2029)
Figure 54. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity Market Share by Region (2018-2029)
Figure 55. Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value Market Share by Region (2018-2029)
Figure 56. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. Australia PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 62. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity Market Share by Type (2018-2029)
Figure 63. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity Market Share by Application (2018-2029)
Figure 64. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity Market Share by Country (2018-2029)
Figure 65. South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value Market Share by Country (2018-2029)
Figure 66. Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 67. Argentina PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 68. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity Market Share by Type (2018-2029)
Figure 69. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity Market Share by Application (2018-2029)
Figure 70. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity Market Share by Region (2018-2029)
Figure 71. Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value Market Share by Region (2018-2029)
Figure 72. Turkey PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Egypt PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Saudi Arabia PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. South Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 76. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Drivers
Figure 77. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Restraints
Figure 78. PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Trends
Figure 79. Porters Five Forces Analysis
Figure 80. Manufacturing Cost Structure Analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor in 2022
Figure 81. Manufacturing Process Analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor
Figure 82. PARP (Poly ADP-Ribose Polymerase) Inhibitor Industrial Chain
Figure 83. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 84. Direct Channel Pros & Cons
Figure 85. Indirect Channel Pros & Cons
Figure 86. Methodology
Figure 87. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
